# Guerrilla RF, Inc.: financial statements, quarterly

GUER · OTC · CIK 1832487 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/guer.md) · [Financials](/companies/guer/financials.md) · [Filings](/companies/guer/filings.md) · [Insiders](/companies/guer/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/guer/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3,366](/filings/0001437749-24-035030.md) | [4,702 d](/filings/0001437749-25-009538.md) | [5,091](/filings/0001437749-25-016378.md) | [6,111](/filings/0001437749-25-026052.md) | [4,524](/filings/0001437749-25-034245.md) | [4,390 d](/filings/0001437749-26-009848.md) | [4,373](/filings/0001437749-26-016568.md) | [5,369](/filings/0001437749-26-027155.md) | [6,288](/filings/0001437749-25-034245.md) | [6,700 d](/filings/0001437749-26-009848.md) | [6,462](/filings/0001437749-26-016568.md) | [8,012](/filings/0001437749-26-027155.md) |
| Cost of revenue | $k | [1,491](/filings/0001437749-24-035030.md) | [2,029 d](/filings/0001437749-25-009538.md) | [1,871](/filings/0001437749-25-016378.md) | [2,120](/filings/0001437749-25-026052.md) | [1,571](/filings/0001437749-25-034245.md) | [1,740 d](/filings/0001437749-26-009848.md) | [1,703](/filings/0001437749-26-016568.md) | [1,885](/filings/0001437749-26-027155.md) | [2,043](/filings/0001437749-25-034245.md) | [2,249 d](/filings/0001437749-26-009848.md) | [1,945](/filings/0001437749-26-016568.md) | [2,331](/filings/0001437749-26-027155.md) |
| Gross profit | $k | [1,875](/filings/0001437749-24-035030.md) | [2,673 d](/filings/0001437749-25-009538.md) | [3,221](/filings/0001437749-25-016378.md) | [3,990](/filings/0001437749-25-026052.md) | [2,953](/filings/0001437749-25-034245.md) | [2,650 d](/filings/0001437749-26-009848.md) | [2,670](/filings/0001437749-26-016568.md) | [3,484](/filings/0001437749-26-027155.md) | [4,245](/filings/0001437749-25-034245.md) | [4,451 d](/filings/0001437749-26-009848.md) | [4,517](/filings/0001437749-26-016568.md) | [5,681](/filings/0001437749-26-027155.md) |
| Research and development | $k | [2,775](/filings/0001437749-24-035030.md) | [2,268 d](/filings/0001437749-25-009538.md) | [2,252](/filings/0001437749-25-016378.md) | [2,413](/filings/0001437749-25-026052.md) | [2,507](/filings/0001437749-25-034245.md) | [2,537 d](/filings/0001437749-26-009848.md) | [2,493](/filings/0001437749-26-016568.md) | [2,170](/filings/0001437749-26-027155.md) | [1,970](/filings/0001437749-25-034245.md) | [1,921 d](/filings/0001437749-26-009848.md) | [1,984](/filings/0001437749-26-016568.md) | [2,073](/filings/0001437749-26-027155.md) |
| Operating income | $k | [(3,727)](/filings/0001437749-24-035030.md) | [(2,100) d](/filings/0001437749-25-009538.md) | [(1,839)](/filings/0001437749-25-016378.md) | [(1,197)](/filings/0001437749-25-026052.md) | [(2,610)](/filings/0001437749-25-034245.md) | [(3,118) d](/filings/0001437749-26-009848.md) | [(3,162)](/filings/0001437749-26-016568.md) | [(1,355)](/filings/0001437749-26-027155.md) | [(198)](/filings/0001437749-25-034245.md) | [54.7 d](/filings/0001437749-26-009848.md) | [(46.3)](/filings/0001437749-26-016568.md) | [964](/filings/0001437749-26-027155.md) |
| Interest expense | $k | [732](/filings/0001437749-24-035030.md) | [1,442 d](/filings/0001437749-25-009538.md) | [1,685](/filings/0001437749-25-016378.md) | [856](/filings/0001437749-25-026052.md) | [501](/filings/0001437749-25-034245.md) | [225 d](/filings/0001437749-26-009848.md) | [211](/filings/0001437749-26-016568.md) | [242](/filings/0001437749-26-027155.md) | [292](/filings/0001437749-25-034245.md) | [241 d](/filings/0001437749-26-009848.md) | [204](/filings/0001437749-26-016568.md) | [219](/filings/0001437749-26-027155.md) |
| Income tax | $k | [0.0](/filings/0001437749-23-031540.md) | [0.0 d](/filings/0001437749-25-009538.md) | [0.0](/filings/0001437749-24-016686.md) | [0.0 d](/filings/0001437749-24-026159.md) | [0.0 d](/filings/0001437749-24-035030.md) | [0.0 d](/filings/0001437749-26-009848.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(4,481)](/filings/0001437749-24-035030.md) | [(3,663) d](/filings/0001437749-25-009538.md) | [(3,373)](/filings/0001437749-25-034245.md) | [(1,757)](/filings/0001437749-25-034245.md) | [(7,202)](/filings/0001437749-25-034245.md) | [1,578 d](/filings/0001437749-26-009848.md) | [(3,543)](/filings/0001437749-26-027155.md) | [(471)](/filings/0001437749-26-027155.md) | [(645)](/filings/0001437749-25-034245.md) | [(2,328) d](/filings/0001437749-26-009848.md) | [1,122](/filings/0001437749-26-027155.md) | [(2,233)](/filings/0001437749-26-027155.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [(0.34)](/filings/0001437749-26-016568.md) | not reported | not reported | not reported | [0.06](/filings/0001437749-26-016568.md) | not reported |
| Basic EPS | $ per share | [(0.62)](/filings/0001437749-24-035030.md) | not reported | [(0.42)](/filings/0001437749-25-016378.md) | [(0.17)](/filings/0001437749-25-026052.md) | [(0.71)](/filings/0001437749-25-034245.md) | not reported | [(0.34)](/filings/0001437749-26-016568.md) | [(0.05)](/filings/0001437749-26-027155.md) | [(0.06)](/filings/0001437749-25-034245.md) | not reported | [0.06](/filings/0001437749-26-016568.md) | [(0.21)](/filings/0001437749-26-027155.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.9](/filings/0001437749-23-031540.md) | [0.8](/filings/0001437749-25-009538.md) | [3.6](/filings/0001437749-24-016686.md) | [0.6](/filings/0001437749-24-026159.md) | [11.3](/filings/0001437749-24-035030.md) | [8.0](/filings/0001437749-26-009848.md) | [6.1](/filings/0001437749-25-016378.md) | [4.8](/filings/0001437749-25-026052.md) | [4.0](/filings/0001437749-25-034245.md) | [4.2](/filings/0001437749-26-027155.md) | [3.2](/filings/0001437749-26-016568.md) | [4.6](/filings/0001437749-26-027155.md) |
| Current assets | $m | [4.6](/filings/0001437749-23-031540.md) | [4.9](/filings/0001437749-25-009538.md) | [8.7](/filings/0001437749-24-016686.md) | [4.9](/filings/0001437749-24-026159.md) | [15.2](/filings/0001437749-24-035030.md) | [12.5](/filings/0001437749-26-009848.md) | [10.3](/filings/0001437749-25-016378.md) | [9.8](/filings/0001437749-25-026052.md) | [8.3](/filings/0001437749-25-034245.md) | [8.1](/filings/0001437749-26-027155.md) | [9.7](/filings/0001437749-26-016568.md) | [10.2](/filings/0001437749-26-027155.md) |
| Total assets | $m | [19.7](/filings/0001437749-23-031540.md) | [19.0](/filings/0001437749-25-009538.md) | [22.3](/filings/0001437749-24-016686.md) | [18.2](/filings/0001437749-24-026159.md) | [28.2](/filings/0001437749-24-035030.md) | [24.9](/filings/0001437749-26-009848.md) | [22.3](/filings/0001437749-25-016378.md) | [21.9](/filings/0001437749-25-026052.md) | [20.2](/filings/0001437749-25-034245.md) | [19.5](/filings/0001437749-26-027155.md) | [20.6](/filings/0001437749-26-016568.md) | [20.8](/filings/0001437749-26-027155.md) |
| Current liabilities | $m | [13.4](/filings/0001437749-23-031540.md) | [17.3](/filings/0001437749-25-009538.md) | [8.1](/filings/0001437749-24-016686.md) | [5.5](/filings/0001437749-24-026159.md) | [11.3](/filings/0001437749-24-035030.md) | [6.2](/filings/0001437749-26-009848.md) | [7.1](/filings/0001437749-25-016378.md) | [7.2](/filings/0001437749-25-026052.md) | [6.3](/filings/0001437749-25-034245.md) | [7.8](/filings/0001437749-26-027155.md) | [7.9](/filings/0001437749-26-016568.md) | [10.2](/filings/0001437749-26-027155.md) |
| Total liabilities | $m | [23.2](/filings/0001437749-23-031540.md) | [25.8](/filings/0001437749-25-009538.md) | [26.3](/filings/0001437749-24-016686.md) | [23.6](/filings/0001437749-24-026159.md) | [23.0](/filings/0001437749-24-035030.md) | [17.1](/filings/0001437749-26-009848.md) | [17.7](/filings/0001437749-25-016378.md) | [17.5](/filings/0001437749-25-026052.md) | [16.2](/filings/0001437749-25-034245.md) | [17.7](/filings/0001437749-26-027155.md) | [17.5](/filings/0001437749-26-016568.md) | [19.6](/filings/0001437749-26-027155.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(3.5)](/filings/0001437749-24-035030.md) | [(6.8)](/filings/0001437749-26-009848.md) | [(4.0)](/filings/0001437749-25-034245.md) | [(5.4)](/filings/0001437749-25-034245.md) | [(14.9)](/filings/0001437749-25-034245.md) | [(12.2)](/filings/0001437749-26-027155.md) | [(15.4)](/filings/0001437749-26-027155.md) | [(15.6)](/filings/0001437749-26-027155.md) | [(16.1)](/filings/0001437749-25-034245.md) | [(18.2)](/filings/0001437749-26-027155.md) | [(16.9)](/filings/0001437749-26-027155.md) | [(18.8)](/filings/0001437749-26-027155.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,248) d](/filings/0001437749-24-035030.md) | [(2,276) d](/filings/0001437749-25-009538.md) | [(842)](/filings/0001437749-25-016378.md) | [(1,175) d](/filings/0001437749-25-026052.md) | [(1,773) d](/filings/0001437749-25-034245.md) | [(2,863) d](/filings/0001437749-26-009848.md) | [(2,263)](/filings/0001437749-26-016568.md) | [(1,082) d](/filings/0001437749-26-027155.md) | [900](/filings/0001437749-26-009848.md) | [1,100](/filings/0001437749-26-009848.md) | [(1,254)](/filings/0001437749-26-016568.md) | [2,427 d](/filings/0001437749-26-027155.md) |
| Capital expenditure | $k | [45.3 d](/filings/0001437749-24-035030.md) | [(36.8) d](/filings/0001437749-25-009538.md) | [26.0](/filings/0001437749-25-016378.md) | [85.1 d](/filings/0001437749-25-026052.md) | [192 d](/filings/0001437749-25-034245.md) | [78.3 d](/filings/0001437749-26-009848.md) | [47.3](/filings/0001437749-26-016568.md) | [512 d](/filings/0001437749-26-027155.md) | [614 d](/filings/0001437749-25-034245.md) | [204 d](/filings/0001437749-26-009848.md) | [63.2](/filings/0001437749-26-016568.md) | [161 d](/filings/0001437749-26-027155.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001437749-22-012193.md) | [10.3](/filings/0001437749-26-016568.md) | [17.9](/filings/0001437749-26-016568.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,698,651 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027155.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.